H2020Индивидуална стипендия2021–2023

SENAGE · Senescence as a key factor in leukemogenesis and bone marrow homeostasis in aging

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-09-01 → 2023-12-21
Финансиране от ЕС: 172 932 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Процесите на стареене и клетъчното заспиване се изследват при пациенти с хронична лимфоцитна и остра миелоидна левкемия. Разбирането на тези механизми помага за откриване на нови маркери и терапии с по-малко странични ефекти.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Senescence as a key factor in leukemogenesis and bone marrow homeostasis in aging

Cancer is a significant health concern and a leading cause of death worldwide. In Europe, and the United States, it stands as the second leading cause of death. While cancer can affect people at any age, getting older is a major risk factor. Aging is a complex process where our bodies gradually decline in function, and changes in how our genes are regulated, called epigenetic changes, are also associated with aging. Similar changes occur at the cellular level in a process called senescence, which limits the growth of aging or damaged cells, acting like a natural defense against the formation of tumors. However, cancer cells can find ways to escape this mechanism. Chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) are common types of blood cancers, typically diagnosed around the age of 68. Their occurrence is rare in younger individuals but increases with age. This highlights the need to investigate how aging processes may contribute to these types of cancers. By understanding these mechanisms, we can identify new targets for treatment and prevention. Our research project has identified specific marks associated with aging in patients with these blood cancers, suggesting that these marks may be linked to how the cancer cells develop. Moreover, this information has helped us discover potential biomarkers, which, if validated in further studies, could be associated with how well a therapy works. Importantly, this therapy has properties that target senescent cells more effectively than regular chemotherapy, potentially leading to fewer side effects. The findings from our project connect the dots between cancer genetics, the aging process, senescence, and the development of blood cancers.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Cancer is a major public health problem and one of the leading causes of death worldwide. In particular, it has been the second cause of death in Spain, Europe and United States. Although cancer can occur at any age, aging is one of the main risk factors for its development. Aging is a complex scarcely understood multi-step process associated with the gradual functional decline of organs and systems. In addition, age-dependent changes in epigenetic regulation occur, indicating that epigenetic regulation may also play an important role in aging. Similar changes have been observed at the cellular level in a mechanism known as senescence. This mechanism is a cellular response that limits the proliferation of aged or damaged cells, behaving as a tumor suppressor mechanism and transformation events lead to escape from it.Chronic lymphocytic leukemia and acute myeloid leukemia are the most frequent types of leukemias and have median ages at diagnosis of 68 years. Both have a low incidence in the young population and increase with age. Thus, it is important to explore novel approaches to understand the mechanisms of aging favoring these types of leukemias, thereby unraveling new target molecules for treatment and prevention. We propose to explore the senescence epigenetic profile in leukemic cells, the impact of senolytic drugs in patients and in the development of AML in spontaneous animal model. The approach will bridge cancer epigenetics with senescence, aging and leukemogenesis.This proposal will augment my scientific knowledge and practical skills. In addition, the complementary planned activities of the action will provide me to the additional tools to become an independent investigator in the near future.

Оригинален текст от CORDIS (на английски).

Участници

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS · BadalonaКоординаторИспания